

<https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than, October 21, 2022.

*A. Federal Reserve Bank of Boston* (Prabal Chakrabarti, Senior Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02210-2204, or electronically to [BOS.SRC.Applications.Comments@bos.frb.org](mailto:BOS.SRC.Applications.Comments@bos.frb.org):

1. *The Vanguard Group, Inc., Malvern, Pennsylvania; on behalf of itself, its subsidiaries and affiliates, including investment companies registered under the Investment Company Act of 1940, other pooled investment vehicles, and institutional accounts that are sponsored, managed, or advised by Vanguard*; to acquire additional voting shares of Berkshire Hills Bancorp, Inc., Boston, Massachusetts, and thereby indirectly acquire additional voting shares of Berkshire Bank, Pittsfield, Massachusetts.

2. *The Vanguard Group, Inc., Malvern, Pennsylvania; on behalf of itself, its subsidiaries and affiliates, including investment companies registered under the Investment Company Act of 1940, other pooled investment vehicles, and institutional accounts that are sponsored, managed, or advised by Vanguard*; to acquire additional voting shares of Brookline Bancorp, Inc., Boston, Massachusetts, and thereby indirectly acquire voting shares of Brookline Bank, Brookline, Massachusetts and Bank Rhode Island, Providence, Rhode Island.

*B. Federal Reserve Bank of Philadelphia* (William Spaniel, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521, or electronically to [Comments.applications@phil.frb.org](mailto:Comments.applications@phil.frb.org):

1. *The Vanguard Group, Inc., Malvern, Pennsylvania; on behalf of itself, its subsidiaries and affiliates, including investment companies registered under the Investment Company Act of 1940, other pooled investment vehicles, and institutional accounts that are sponsored, managed, or advised by Vanguard*; to acquire additional voting shares of WSFS Financial Corporation, and thereby indirectly acquire additional voting shares of Wilmington Savings Fund

Society, FSB, both of Wilmington, Delaware.

*C. Federal Reserve Bank of Cleveland* (Bryan S. Huddleston, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101-2566, or electronically to [Comments.applications@clev.frb.org](mailto:Comments.applications@clev.frb.org):

1. *The Vanguard Group, Inc., Malvern, Pennsylvania; on behalf of itself, its subsidiaries and affiliates, including investment companies registered under the Investment Company Act of 1940, other pooled investment vehicles, and institutional accounts that are sponsored, managed, or advised by Vanguard*; to acquire additional voting shares of Macy's, Inc., New York, New York, and thereby indirectly acquire additional voting shares of FDS Bank, Mason, Ohio.

2. *The Vanguard Group, Inc., Malvern, Pennsylvania; on behalf of itself, its subsidiaries and affiliates, including investment companies registered under the Investment Company Act of 1940, other pooled investment vehicles, and institutional accounts that are sponsored, managed, or advised by Vanguard*; to acquire additional voting shares of Northwest Bancshares, Inc., Columbus, Ohio, and thereby indirectly acquire additional voting shares of Northwest Bank, Warren, Pennsylvania.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell**,

*Deputy Associate Secretary of the Board.*

[FR Doc. 2022-21795 Filed 10-5-22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Community Living

#### 2022 National Strategy To Support Family Caregivers Available for Public Comments

**AGENCY:** Department of Health and Human Services/Administration for Community Living.

**ACTION:** Notice of 60-day public comment period.

**SUMMARY:** In accordance with the requirements of the Recognize, Assist, Include, Support and Engage (RAISE) Family Caregivers Act of 2017, the Administration for Community Living (ACL) is making the 2022 National Strategy to Support Family Caregivers (the Strategy) available for public comment for a period of 60 days. Public comments received will be used to inform the ongoing work of the Family Caregiving Advisory Council and the

Advisory Council to Support Grandparents Raising Grandchildren, as well as to inform future updates to the Strategy.

**DATES:** Submit comments on or before November 30, 2022.

**Submission:** The 2022 National Strategy to Support Family Caregivers is available at: <https://acl.gov/CaregiverStrategy>. Submit all comments via the online form available at: <https://acl.gov/CaregiverStrategy/Comments>.

**FOR FURTHER INFORMATION CONTACT:** Greg Link, Director, Office of Supportive and Caregiver Services, Administration for Community Living, via email at [raise.mail@acl.hhs.gov](mailto:raise.mail@acl.hhs.gov) or at (202) 795-7386.

**SUPPLEMENTARY INFORMATION:** The Strategy is intended to serve as a national roadmap for better recognizing and supporting family and kinship caregivers of all ages, backgrounds, and caregiving situations.

It includes nearly 350 actions the federal government will take to support family caregivers in the coming year and more than 150 actions that can be adopted at other levels of government and across the private sector to build a system to support family caregivers.

The strategy was developed jointly by the advisory councils established by the Recognize, Assist, Include, Support, and Engage (RAISE) Family Caregivers Act and the Supporting Grandparents Raising Grandchildren (SGRG) Act, with extensive input from family caregivers, the people they support and other stakeholders. ACL leads implementation of the RAISE and SGRG Acts and facilitates the work of the two advisory councils.

Each year, around 53 million people provide a broad range of assistance to support the health, quality of life and independence of a person close to them who needs assistance as they age or due to a disability or chronic health condition. Another 2.7 million grandparent caregivers—and an unknown number of other relative caregivers—open their arms and homes each year to millions of children who cannot remain with their parents. Millions of older adults and people with disabilities would not be able to live in their communities without this essential support—and replacing it with paid services would cost an estimated \$470 billion each year.

While family caregiving is rewarding, it can be challenging, and when caregivers do not have the support they need, their health, wellbeing and quality of life often suffer. Their financial future can also be put at risk; lost income due to family caregiving is estimated at \$522

billion each year. When the challenges become overwhelming and family caregivers no longer can provide support, the people they care for often are left with no choices except moving to nursing homes and other institutions or to foster care—the cost of which is typically borne by taxpayers.

The strategy represents the first time a broad cross-section of the federal government has collaborated with the private sector on a response to the longstanding national need for a comprehensive system of family caregiver support. It is the product of comprehensive analysis and input from 15 federal agencies and more than 150 organizations representing a range of stakeholders from across the nation. It builds upon the initial reports delivered to Congress in 2021 by the RAISE Family Caregiving Advisory Council and the SGRG Advisory Council.

For more information, see also the RAISE Family Caregiving Advisory Council web page: <https://acl.gov/RAISE/>; the Initial RAISE Family Caregivers Act Report to Congress: <https://acl.gov/RAISE/report/>; the Advisory Council to Support Grandparents Raising Grandchildren web page: <https://acl.gov/SGRG/>; the Initial SGRG Act Report to Congress: <https://acl.gov/SGRG/report/>.

**Solicitation of Public Comments:** ACL is requesting comments on (a) the most important topics/issues for the Advisory Councils to focus on moving forward; and (b) issues that were not covered by the initial strategy that should be addressed in future updates.

Dated: September 30, 2022.

**Alison Barkoff,**

*Acting Administrator and Assistant Secretary for Aging.*

[FR Doc. 2022–21697 Filed 10–5–22; 8:45 am]

BILLING CODE 4154–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2022–N–2337]

#### Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; establishment of a public docket; request for comments.

**SUMMARY:** The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cardiovascular and Renal

Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

**DATES:** The meeting will be held on December 14, 2022, from 9 a.m. to 2 p.m. Eastern Time.

**ADDRESSES:** Please note that due to the impact of this COVID–19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Answers to commonly asked questions about FDA advisory committee meetings, including information regarding special accommodations due to a disability, may be accessed at: <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm>.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA–2022–N–2337. Please note that late, untimely filed comments will not be considered. The docket will close on December 13, 2022. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of December 13, 2022. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Comments received on or before November 29, 2022, will be provided to the committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is canceled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

You may submit comments as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or

anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

#### *Written/Paper Submissions*

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

**Instructions:** All submissions received must include the Docket No. FDA–2022–N–2337 for “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.” Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this